Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
Johnson & Johnson's (JNJ) Phase 3 PAPILLON study showed that RYBREVANT plus chemotherapy extended median overall survival to 34.3 months in EGFR exon 20 insertion mutation-positive lung cancer patients, compared to 27.9 months with chemotherapy alone. This represents the longest reported median OS in this patient population, which historically has a five-year survival rate of just 8%. The results were presented at the IASLC 2026 World Conference on Lung Cancer.
How this was made
The 30-second read
Why it matters
The data represent the longest reported median OS in this patient population, potentially expanding the drug's market share.
Market read
New Phase 3 survival data could drive investor interest in JNJ's oncology franchise and influence biotech sector sentiment.
What to watch
Regulatory filing timeline and potential competition from other EGFR/MET agents could moderate upside.
Background
Johnson & Johnson's RYBREVANT (amivantamab‑vmjw) is already approved for EGFR‑mutated NSCLC; this is the first overall‑survival data for the exon 20 insertion subgroup.
Ticker impact
Johnson & Johnson announced Phase 3 OS results for RYBREVANT plus chemotherapy, showing median overall survival of 34.3 months versus 27.9 months for chemo alone.
Potential modest upside as investors re‑price the lung‑cancer indication.
Phase 3 overall‑survival improvement is material, first‑time disclosed, and aligns with JNJ's growth strategy in oncology.
Market effects
Strengthens the biotech/oncology sector outlook, may lift peers with EGFR‑targeted assets.
Positive for US pharma stocks and Asian markets where lung‑cancer incidence is high.
Adds to global confidence in bispecific antibody platforms.
Counterpoint
If crossover dilutes the survival benefit, the data may be less compelling, limiting price reaction.
Key entities
- CompanyJohnson & Johnson
Pharmaceutical giant reporting the trial results.
- DrugRYBREVANT
Bispecific antibody targeting EGFR and MET.
